Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Bone: Angiosarcoma

Written2008-02Sofie LJ Verbeke, Judith VMG Bovée
Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
Updated2016-11David G.P. van Ijzendoorn and Judith V.M.G. Bovée
Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. J.V.M.G.Bovee@lumc.nl

(Note : for Links provided by Atlas : click)

Abstract

Abstract Review on Angiosarcoma of bones, with data on clinics, and the genes involved.

Identity

ICD-Topo C400-C403,C408-C414,C418-C419 BONES & JOINTS
ICD-Morpho 9120/3 Hemangiosarcoma
Atlas_Id 5359
Phylum Bones::Angiosarcoma
Other namesPrimary malignant vascular tumours of bone
Note Variable proliferation of tumour cells which show an endothelial phenotype
Microscopy - PMVTB: epithelioid morphology - HE (10x)

Classification

Note Angiosarcoma is a high grade primary malignant vascular tumour of bone as recognized in the 2013 World Health Organization (WHO) classification. It can sometimes be difficult to histologically distinguish angiosarcoma from Epithelioid haemangioendothelioma as they can show overlapping morphology , but recently multiple fusion genes and mutations have been identified that can help in the differential diagnosis. The prognosis for angiosarcoma is generally very poor.

Clinics and Pathology

Disease Primary malignant vascular tumours of bone
Etiology Although there is in a very small percentage an association between angiosarcoma and radiation, the etiology of the majority of angiosarcomas remains unknown.
Epidemiology Angiosarcoma is extremely rare and represent less than 1% of primary malignant bone tumours.
Clinics Angiosarcomas of bone arise in adults and have a wide, nearly equal age distribution from the second till eighth decade. In contrast to epithelioid haemangioendotheliomas have a tendency to occur in young adults (second - third decade). It seems that males are slightly more affected than females.
Angiosarcomas of bone have a wide skeletal distribution; however, they have a tendency to occur in the short and long tubular bones of the extremities of which the femur, tibia and humerus are most often affected. In contrast to the soft tissue counterpart, one third of the tumours are multifocal, involving two or more distant bones.
In general, malignant vascular tumours of bone present as a painful mass. Depending on the size and localization of the tumour, neurological deficit or other symptoms can occur.
Pathology Similar to the soft tissue counterpart ( Angiosarcoma of the soft tissue), malignant vascular tumours of bone have variable histological features, varying from well differentiated to poor differentiated lesions. To a certain extent, the formation of vascular channels is one of the most common referred hallmarks of this tumour. These lesions show a variable amount of mitotic features, atypical mitotic figures, necrosis and cytonuclear atypia. Cells can have a spindle cell or an epithelioid morphology.
Treatment Prefered therapy, whenever possible, is surgical intervention (wide en bloc resection or amputation). Moreover radiotherapy is also applied, although there is no general rule for treatment. Treatment depends upon multiple factors, such as age, size, location of the tumour, and the extent of disease. Chemotherapy is used, although its usefulness is not well documented.
Prognosis Angiosarcoma of bone has 33% 5 year overall survival. When primary angiosarcoma of bone exhibits more than 3 mitosis per 10 HPF with prominent nucleolus and fewer than five eosinophilic granulocytes per 10 HPF they will likely have a worse prognosis.

Genetics

Note Recently mutations and amplifications have been described for angiosarcoma, most of these aberrations occur in the tyrosine-kinase pathways specific for vascular receptors. Currently PTPRB, PLCG1, CIC, KDR, and FLT4 mutations and MYC amplifications. have been described for angiosarcoma. There is no evidence that there is a molecular genetic difference between angiosarcoma of bone and angiosarcoma occurring in soft tissue.

Bibliography

Malignant vascular tumors--an update
Antonescu C
Modern Pathology (2014) 27, S30-S38; doi:10.1038/modpathol.2013.176
PMID 24384851
 
Recurrent PTPRB and PLCG1 mutations in angiosarcoma
Behjati S, Tarpey PS, Sheldon H, Martincorena I, Van Loo P, Gundem G, Wedge DC, Ramakrishna M, Cooke SL, Pillay N, Vollan HK, Papaemmanuil E, Koss H, Bunney TD, Hardy C, Joseph OR, Martin S, Mudie L, Butler A, Teague JW, Patil M, Steers G, Cao Y, Gumbs C, Ingram D, Lazar AJ, Little L, Mahadeshwar H, Protopopov A, Al Sannaa GA, Seth S, Song X, Tang J, Zhang J, Ravi V, Torres KE, Khatri B, Halai D, Roxanis I, Baumhoer D, Tirabosco R, Amary MF, Boshoff C, McDermott U, Katan M, Stratton MR, Futreal PA, Flanagan AM, Harris A, Campbell PJ.
Nat Genet. 2014 Apr;46(4):376-9. doi: 10.1038/ng.2921.
PMID 24633157
 
Vascular tumors of bone: A study of 17 cases other than ordinary hemangioma, with an evaluation of the relationship of hemangioendothelioma of bone to epithelioid hemangioma, epithelioid hemangioendothelioma, and high-grade angiosarcoma.
Evans HL, Raymond AK, Ayala AG
Human pathology. 2003 ; 34 (7) : 680-689.
PMID 12874764
 
World Health Organization Classification of Tumours: Pathology and genetics of tumours of soft tissue and bone.
Fletcher CDM, Krishnan Unni K, Mertens F
IARCpress Lyon,. 2002.
 
Total resection of an intracerebral hemangioendothelioma in an infant. Case report and review of the literature.
Hodaie M, Becker L, Teshima I, Rutka JT
Pediatric neurosurgery. 2001 ; 34 (2) : 104-112.
PMID 11287811
 
Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations
Huang SC, Zhang L, Sung YS, Chen CL, Kao YC, Agaram NP, Singer S, Tap WD, D'Angelo S, Antonescu CR
Am J Surg Pathol 2016;00:000-000
PMID 26735859
 
Bone Tumors. Clinical, radiologic and pathologic correlations.
Mirra JM
Lea..
 
Post-irradiation angiosarcoma of bone.
Mittal S, Goswami C, Kanoria N, Bhattacharya A
Journal of cancer research and therapeutics. 2007 ; 3 (2) : 96-99.
PMID 17998731
 
Epithelioid vascular tumors of bone: a review and proposal of a classification scheme.
O'Connell JX, Nielsen GP, Rosenberg AE
Advances in anatomic pathology. 2001 ; 8 (2) : 74-82.
PMID 11236956
 
Chromosome analysis and molecular cytogenetic investigations of an epithelioid hemangioendothelioma.
Tsarouha H, Kyriazoglou AI, Ribeiro FR, Teixeira MR, Agnantis N, Pandis N
Cancer genetics and cytogenetics. 2006 ; 169 (2) : 164-168.
PMID 16938576
 
Distinct histological features characterize primary angiosarcoma of bone
Verbeke SL, Bertoni F, Bacchini P, Sciot R, Fletcher CD, Kroon HM, Hogendoorn PC, Bovée JV
(2011) Histopathology 58, 254-264
PMID 21323951
 
Malignant vascular lesions of bone: radiologic and pathologic features.
Wenger DE, Wold LE
Skeletal radiology. 2000 ; 29 (11) : 619-631.
PMID 11201031
 

Citation

This paper should be referenced as such :
van Ijzendoorn DGP, Bovée JVMG
Bone: Angiosarcom
Atlas Genet Cytogenet Oncol Haematol. in press
On line version : http://AtlasGeneticsOncology.org/Tumors/BoneAngiosarcID5359.html
History of this paper:
Verbeke, SLJ ; Bove, JVMG. Bone: Angiosarcoma. Atlas Genet Cytogenet Oncol Haematol. 2009;13(2):147-148.
http://documents.irevues.inist.fr/bitstream/handle/2042/44415/02-2008-BoneAngiosarcID5359.pdf


External links

arrayMap Topo ( C40,C41) arrayMap ((UZH-SIB Zurich)   [auto + random 100 samples .. if exist ]   [tabulated segments]
 
 
Other databasehttp://cgap.nci.nih.gov/Chromosomes/AbnCytSearchForm
Disease databaseBone: Angiosarcoma
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Sep 26 12:36:57 CEST 2017


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.